"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_institute","contact_address","contact_city","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","er(ps):ch1","her2(ihc):ch1","ki-67:ch1","metastasis status:ch1","pgr(ps):ch1","tissue:ch1"
"GSM3937321","BC0342","GSM3937321","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 45","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 94","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937321/suppl/GSM3937321_SH4XY09_Cell2.txt.gz","2540","45","1","0","94","Metastasis","1","Serum"
"GSM3937322","BC0393","GSM3937322","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 49","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937322/suppl/GSM3937322_SH4XY25_Cell1.txt.gz","2540","49","0","0","NA","Metastasis","0","Serum"
"GSM3937323","BC0395","GSM3937323","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 27","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.821","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937323/suppl/GSM3937323_SH4XY25_Cell3.txt.gz","2540","27","0","0","0.821","Metastasis","0","Serum"
"GSM3937324","BC0524","GSM3937324","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 53","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 82.9","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937324/suppl/GSM3937324_SH4XZ48_Cell1.txt.gz","2540","53","0","0","82.9","Metastasis","0","Serum"
"GSM3937325","BC0697","GSM3937325","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 46","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 70.7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937325/suppl/GSM3937325_SH46351_Cell4.txt.gz","2540","46","0","0","70.7","Metastasis","0","Serum"
"GSM3937372","BC0666","GSM3937372","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 44","er(ps): 1","pgr(ps): 1","her2(ihc): 1","ki-67: 73.4","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937372/suppl/GSM3937372_SH4Y425_Cell3.txt.gz","2540","44","1","1","73.4","no-Metastasis","1","Serum"
"GSM3937373","BC0676","GSM3937373","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 67","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937373/suppl/GSM3937373_SH4Y428_Cell1.txt.gz","2540","67","0","0","NA","no-Metastasis","0","Serum"
"GSM3937374","BC0708","GSM3937374","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 55","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL18941","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937374/suppl/GSM3937374_SH46355_Cell1.txt.gz","2540","55","0","0","NA","no-Metastasis","0","Serum"
"GSM3937326","BC1717","GSM3937326","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 65","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937326/suppl/GSM3937326_SH67M06_Cell2.txt.gz","2540","65","0","1","NA","Metastasis","0","Serum"
"GSM3937327","BC1721","GSM3937327","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 44","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937327/suppl/GSM3937327_SH67M07_Cell2.txt.gz","2540","44","0","1","NA","Metastasis","0","Serum"
"GSM3937328","BC1727","GSM3937328","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 55","er(ps): NA","pgr(ps): NA","her2(ihc): NA","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937328/suppl/GSM3937328_SH67M09_Cell4.txt.gz","2540","55","NA","NA","NA","Metastasis","NA","Serum"
"GSM3937329","BC1729","GSM3937329","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 82","er(ps): NA","pgr(ps): NA","her2(ihc): NA","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937329/suppl/GSM3937329_SH66D07_Cell2.txt.gz","2540","82","NA","NA","NA","Metastasis","NA","Serum"
"GSM3937330","BC1732","GSM3937330","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 36","er(ps): 0","pgr(ps): 0","her2(ihc): NA","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937330/suppl/GSM3937330_SH66D09_Cell1.txt.gz","2540","36","0","NA","NA","Metastasis","0","Serum"
"GSM3937331","BC1733","GSM3937331","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 63","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937331/suppl/GSM3937331_SH66D09_Cell2.txt.gz","2540","63","0","1","NA","Metastasis","0","Serum"
"GSM3937332","BC1734","GSM3937332","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 44","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937332/suppl/GSM3937332_SH66D09_Cell3.txt.gz","2540","44","0","0","30","Metastasis","0","Serum"
"GSM3937333","BC1735","GSM3937333","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 61","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937333/suppl/GSM3937333_SH66D09_Cell4.txt.gz","2540","61","0","0","NA","Metastasis","0","Serum"
"GSM3937334","BC1736","GSM3937334","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 63","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937334/suppl/GSM3937334_SH66D10_Cell1.txt.gz","2540","63","0","1","NA","Metastasis","0","Serum"
"GSM3937335","BC1737","GSM3937335","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 62","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937335/suppl/GSM3937335_SH66D10_Cell2.txt.gz","2540","62","1","0","NA","Metastasis","1","Serum"
"GSM3937336","BC1739","GSM3937336","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 66","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937336/suppl/GSM3937336_SH66D10_Cell4.txt.gz","2540","66","0","0","NA","Metastasis","0","Serum"
"GSM3937337","BC1740","GSM3937337","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 63","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937337/suppl/GSM3937337_SH66D11_Cell1.txt.gz","2540","63","0","0","NA","Metastasis","0","Serum"
"GSM3937338","BC1741","GSM3937338","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 43","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937338/suppl/GSM3937338_SH66D11_Cell2.txt.gz","2540","43","0","1","NA","Metastasis","0","Serum"
"GSM3937339","BC1742","GSM3937339","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 50","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937339/suppl/GSM3937339_SH66D11_Cell3.txt.gz","2540","50","1","0","NA","Metastasis","1","Serum"
"GSM3937340","BC1744","GSM3937340","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 39","er(ps): 1","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937340/suppl/GSM3937340_SH67M10_Cell1.txt.gz","2540","39","1","1","NA","Metastasis","0","Serum"
"GSM3937341","BC1746","GSM3937341","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 40","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937341/suppl/GSM3937341_SH67T59_Cell4.txt.gz","2540","40","0","0","NA","Metastasis","0","Serum"
"GSM3937342","BC1747","GSM3937342","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 56","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937342/suppl/GSM3937342_SH67T60_Cell1.txt.gz","2540","56","0","1","NA","Metastasis","0","Serum"
"GSM3937343","BC1748","GSM3937343","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 55","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937343/suppl/GSM3937343_SH67M11_Cell1.txt.gz","2540","55","0","1","NA","Metastasis","0","Serum"
"GSM3937344","BC1749","GSM3937344","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 68","er(ps): NA","pgr(ps): NA","her2(ihc): NA","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937344/suppl/GSM3937344_SH67M11_Cell2.txt.gz","2540","68","NA","NA","NA","Metastasis","NA","Serum"
"GSM3937345","BC1750","GSM3937345","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 64","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937345/suppl/GSM3937345_SH67M11_Cell3.txt.gz","2540","64","0","0","NA","Metastasis","0","Serum"
"GSM3937346","BC1752","GSM3937346","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 76","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937346/suppl/GSM3937346_SH67M12_Cell1.txt.gz","2540","76","0","0","NA","Metastasis","0","Serum"
"GSM3937347","BC1753","GSM3937347","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 56","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937347/suppl/GSM3937347_SH67M12_Cell2.txt.gz","2540","56","0","1","NA","Metastasis","0","Serum"
"GSM3937348","BC1756","GSM3937348","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 61","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937348/suppl/GSM3937348_SH67M13_Cell1.txt.gz","2540","61","0","0","0","Metastasis","0","Serum"
"GSM3937349","BC1757","GSM3937349","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 50","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: 32.8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937349/suppl/GSM3937349_SH67M13_Cell2.txt.gz","2540","50","0","1","32.8","Metastasis","0","Serum"
"GSM3937350","BC1758","GSM3937350","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 70","er(ps): 1","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937350/suppl/GSM3937350_SH67M13_Cell3.txt.gz","2540","70","1","0","NA","Metastasis","0","Serum"
"GSM3937351","BC1759","GSM3937351","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 62","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937351/suppl/GSM3937351_SH67M13_Cell4.txt.gz","2540","62","1","0","NA","Metastasis","1","Serum"
"GSM3937352","BC1762","GSM3937352","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 53","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937352/suppl/GSM3937352_SH67M14_Cell3.txt.gz","2540","53","0","0","NA","Metastasis","0","Serum"
"GSM3937353","BC1763","GSM3937353","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 49","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 19.6","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937353/suppl/GSM3937353_SH67M14_Cell4.txt.gz","2540","49","0","0","19.6","Metastasis","0","Serum"
"GSM3937354","BC1764","GSM3937354","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 66","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: 50.8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937354/suppl/GSM3937354_SH67M15_Cell1.txt.gz","2540","66","0","1","50.8","Metastasis","0","Serum"
"GSM3937355","BC1766","GSM3937355","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 35","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.814","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937355/suppl/GSM3937355_SH67M15_Cell3.txt.gz","2540","35","0","0","0.814","Metastasis","0","Serum"
"GSM3937356","BC1769","GSM3937356","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 59","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: 0.433","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937356/suppl/GSM3937356_SH67M16_Cell2.txt.gz","2540","59","0","1","0.433","Metastasis","0","Serum"
"GSM3937357","BC1770","GSM3937357","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 47","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937357/suppl/GSM3937357_SH67M16_Cell3.txt.gz","2540","47","1","0","NA","Metastasis","1","Serum"
"GSM3937358","BC1775","GSM3937358","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 56","er(ps): 1","pgr(ps): 1","her2(ihc): 1","ki-67: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937358/suppl/GSM3937358_SH67M17_Cell4.txt.gz","2540","56","1","1","11","Metastasis","1","Serum"
"GSM3937359","BC1777","GSM3937359","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 42","er(ps): 1","pgr(ps): 0","her2(ihc): 0","ki-67: 81.3","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937359/suppl/GSM3937359_SH67M18_Cell2.txt.gz","2540","42","1","0","81.3","Metastasis","0","Serum"
"GSM3937360","BC1779","GSM3937360","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 53","er(ps): 1","pgr(ps): 0","her2(ihc): 0","ki-67: 83.5","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937360/suppl/GSM3937360_SH67M18_Cell4.txt.gz","2540","53","1","0","83.5","Metastasis","0","Serum"
"GSM3937361","BC1780","GSM3937361","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 70","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.715","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937361/suppl/GSM3937361_SH67M19_Cell1.txt.gz","2540","70","0","0","0.715","Metastasis","0","Serum"
"GSM3937362","BC1783","GSM3937362","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 46","er(ps): 1","pgr(ps): 0","her2(ihc): 1","ki-67: 0.313","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937362/suppl/GSM3937362_SH67M19_Cell4.txt.gz","2540","46","1","1","0.313","Metastasis","0","Serum"
"GSM3937363","BC1784","GSM3937363","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 62","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937363/suppl/GSM3937363_SH67M20_Cell1.txt.gz","2540","62","1","0","NA","Metastasis","1","Serum"
"GSM3937364","BC1788","GSM3937364","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 72","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937364/suppl/GSM3937364_SH67M21_Cell1.txt.gz","2540","72","1","0","NA","Metastasis","1","Serum"
"GSM3937365","BC1791","GSM3937365","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 53","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937365/suppl/GSM3937365_SH67M21_Cell4.txt.gz","2540","53","0","0","0.7","Metastasis","0","Serum"
"GSM3937366","BC1792","GSM3937366","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 62","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 14.8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937366/suppl/GSM3937366_SH67M22_Cell1.txt.gz","2540","62","1","0","14.8","Metastasis","1","Serum"
"GSM3937367","BC1802","GSM3937367","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 52","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.842","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937367/suppl/GSM3937367_SH67M26_Cell3.txt.gz","2540","52","0","0","0.842","Metastasis","0","Serum"
"GSM3937368","BC1805","GSM3937368","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 48","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.569","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937368/suppl/GSM3937368_SH67M27_Cell2.txt.gz","2540","48","0","0","0.569","Metastasis","0","Serum"
"GSM3937369","BC1814","GSM3937369","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 43","er(ps): 0","pgr(ps): 1","her2(ihc): 0","ki-67: 16.4","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937369/suppl/GSM3937369_SH67M30_Cell3.txt.gz","2540","43","0","0","16.4","Metastasis","1","Serum"
"GSM3937370","BC1817","GSM3937370","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 66","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 0.572","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937370/suppl/GSM3937370_SH67M31_Cell2.txt.gz","2540","66","0","0","0.572","Metastasis","0","Serum"
"GSM3937371","BC1818","GSM3937371","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: Metastasis","age: 52","er(ps): 1","pgr(ps): 1","her2(ihc): 1","ki-67: 11.4","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937371/suppl/GSM3937371_SH67M31_Cell3.txt.gz","2540","52","1","1","11.4","Metastasis","1","Serum"
"GSM3937375","BC1745","GSM3937375","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 45","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 46.1","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937375/suppl/GSM3937375_SH67T59_Cell3.txt.gz","2540","45","1","0","46.1","no-Metastasis","1","Serum"
"GSM3937376","BC1755","GSM3937376","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 73","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 75.2","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937376/suppl/GSM3937376_SH67T60_Cell2.txt.gz","2540","73","0","0","75.2","no-Metastasis","0","Serum"
"GSM3937377","BC1767","GSM3937377","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 54","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937377/suppl/GSM3937377_SH67M15_Cell4.txt.gz","2540","54","0","0","77","no-Metastasis","0","Serum"
"GSM3937378","BC1768","GSM3937378","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 78","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 12.5","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937378/suppl/GSM3937378_SH67M16_Cell1.txt.gz","2540","78","1","0","12.5","no-Metastasis","1","Serum"
"GSM3937379","BC1773","GSM3937379","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 35","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937379/suppl/GSM3937379_SH67M17_Cell2.txt.gz","2540","35","0","0","NA","no-Metastasis","0","Serum"
"GSM3937380","BC1774","GSM3937380","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 39","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 75.2","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937380/suppl/GSM3937380_SH67T60_Cell3.txt.gz","2540","39","0","0","75.2","no-Metastasis","0","Serum"
"GSM3937381","BC1776","GSM3937381","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 47","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 6.7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937381/suppl/GSM3937381_SH67M18_Cell1.txt.gz","2540","47","1","0","6.7","no-Metastasis","1","Serum"
"GSM3937382","BC1781","GSM3937382","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 42","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 8.2","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937382/suppl/GSM3937382_SH67M19_Cell2.txt.gz","2540","42","1","0","8.2","no-Metastasis","1","Serum"
"GSM3937383","BC1782","GSM3937383","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 41","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937383/suppl/GSM3937383_SH67M19_Cell3.txt.gz","2540","41","0","0","NA","no-Metastasis","0","Serum"
"GSM3937384","BC1789","GSM3937384","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 61","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937384/suppl/GSM3937384_SH67M21_Cell2.txt.gz","2540","61","1","0","NA","no-Metastasis","1","Serum"
"GSM3937385","BC1795","GSM3937385","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 47","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 92","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937385/suppl/GSM3937385_SH67M22_Cell4.txt.gz","2540","47","0","0","92","no-Metastasis","0","Serum"
"GSM3937386","BC1796","GSM3937386","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 54","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 46..9","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937386/suppl/GSM3937386_SH67M25_Cell1.txt.gz","2540","54","1","0","46..9","no-Metastasis","1","Serum"
"GSM3937387","BC1799","GSM3937387","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 79","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937387/suppl/GSM3937387_SH67M25_Cell4.txt.gz","2540","79","1","0","NA","no-Metastasis","1","Serum"
"GSM3937388","BC1800","GSM3937388","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 38","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 22.5","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937388/suppl/GSM3937388_SH67M26_Cell1.txt.gz","2540","38","1","0","22.5","no-Metastasis","1","Serum"
"GSM3937389","BC1801","GSM3937389","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 45","er(ps): 1","pgr(ps): 0","her2(ihc): 0","ki-67: 90.2","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937389/suppl/GSM3937389_SH67M26_Cell2.txt.gz","2540","45","1","0","90.2","no-Metastasis","0","Serum"
"GSM3937390","BC1804","GSM3937390","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 47","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 40.4","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937390/suppl/GSM3937390_SH67M27_Cell1.txt.gz","2540","47","1","0","40.4","no-Metastasis","1","Serum"
"GSM3937391","BC1806","GSM3937391","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 43","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937391/suppl/GSM3937391_SH67M27_Cell3.txt.gz","2540","43","1","0","NA","no-Metastasis","1","Serum"
"GSM3937392","BC1807","GSM3937392","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 45","er(ps): 0","pgr(ps): 0","her2(ihc): 1","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937392/suppl/GSM3937392_SH67M27_Cell4.txt.gz","2540","45","0","1","NA","no-Metastasis","0","Serum"
"GSM3937393","BC1808","GSM3937393","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 79","er(ps): 0","pgr(ps): 0","her2(ihc): 0","ki-67: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937393/suppl/GSM3937393_SH67M28_Cell1.txt.gz","2540","79","0","0","78","no-Metastasis","0","Serum"
"GSM3937394","BC1809","GSM3937394","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 60","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937394/suppl/GSM3937394_SH67M28_Cell2.txt.gz","2540","60","1","0","NA","no-Metastasis","1","Serum"
"GSM3937395","BC1811","GSM3937395","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 51","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 50.3","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937395/suppl/GSM3937395_SH67M28_Cell4.txt.gz","2540","51","1","0","50.3","no-Metastasis","1","Serum"
"GSM3937396","BC1812","GSM3937396","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 85","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 13.1","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937396/suppl/GSM3937396_SH67M30_Cell1.txt.gz","2540","85","1","0","13.1","no-Metastasis","1","Serum"
"GSM3937397","BC1813","GSM3937397","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 54","er(ps): 1","pgr(ps): 1","her2(ihc): 1","ki-67: 33.2","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937397/suppl/GSM3937397_SH67M30_Cell2.txt.gz","2540","54","1","1","33.2","no-Metastasis","1","Serum"
"GSM3937398","BC1815","GSM3937398","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 51","er(ps): 1","pgr(ps): 1","her2(ihc): 1","ki-67: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937398/suppl/GSM3937398_SH67M30_Cell4.txt.gz","2540","51","1","1","38","no-Metastasis","1","Serum"
"GSM3937399","BC1816","GSM3937399","Public on Sep 04 2019","Jul 10 2019","Sep 04 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","metastasis status: no-Metastasis","age: 46","er(ps): 1","pgr(ps): 1","her2(ihc): 0","ki-67: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetermined) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3937nnn/GSM3937399/suppl/GSM3937399_SH67M31_Cell1.txt.gz","2540","46","1","0","25","no-Metastasis","1","Serum"
